A comparative evaluation of NB30, NB54 and PTC124 in translational read‐through efficacy for treatment of an USH1C nonsense mutation
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Translational read‐through‐inducing drugs (TRIDs) promote read‐through of nonsense mutations, placing them in the spotlight of current gene‐based therapeutic research. Here, we compare for the first time the relative efficacies of new‐generation aminoglycosides NB30, NB54 and the chemical compound PTC124 on retinal toxicity and read‐through efficacy of a nonsense mutation in the USH1C gene, which encodes the scaffold protein harmonin. This mutation causes the human Usher syndrome, the most common form of inherited deaf‐blindness. We quantify read‐through efficacy of the TRIDs in cell culture and show the restoration of harmonin function. We do not observe significant differences in the read‐through efficacy of the TRIDs in retinal cultures; however, we show an excellent biocompatibility in retinal cultures with read‐through versus toxicity evidently superior for NB54 and PTC124. In addition, in vivo administration of NB54 and PTC124 induced recovery of the full‐length harmonin a1 with the same efficacy. The high biocompatibilities combined with the sustained read‐through efficacies of these drugs emphasize the potential of NB54 and PTC124 in treating nonsense mutation‐based retinal disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maerker, T., van Wijk, E., Overlack, N., Kersten, F. F. J., McGee, J., Goldmann, T., Sehn, E., Roepman, R., Walsh, E. J., Kremer, H., et al. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddm285 · Cited by 259 · cited 4×
“We assessed the retinal biocompatibility of NB30, NB54 and PTC124 in organotypic retina cultures, which serve as reliable tools to monitor drug effects on the retina (Goldmann et al, 2010, 2011; Maerker et al, 2008; Orisme et al, 2010; Reidel et al, 2008).”
InfluentialSelf-citation
Cited by
Ataluren treatment of patients with nonsense mutation dystrophinopathy
Bushby, K., Finkel, R., Wong, B., Barohn, R., Campbell, C., Comi, G. P., Connolly, A. M., Day, J. W., Flanigan, K. M., Goemans, N., et al. (2014) · Muscle & Nerve · doi:10.1002/mus.24332 · Cited by 428
Usher syndrome: Hearing loss, retinal degeneration and associated abnormalities
Mathur, P., & Yang, J. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.11.020 · Cited by 330
Therapeutics Based on Stop Codon Readthrough
Keeling, K. M., Xue, X., Gunn, G., & Bedwell, D. M. (2014) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-091212-153527 · Cited by 306
“For example, the NB54 aminoglycoside derivative suppressed nonsense mutations associated with CF, DMD, MPS I-H, Rett syndrome, and Usher syndrome in cultured cells more efficiently than gentamicin (13, 47, 94, 111, 139).”
Molecular Therapies for Inherited Retinal Diseases—Current Standing, Opportunities and Challenges
Vázquez-Domínguez, I., Garanto, A., & Collin, R. W. J. (2019) · Genes · doi:10.3390/genes10090654 · Cited by 80
Metadata
- Authors
- Goldmann, T., Overlack, N., Möller, F., Belakhov, V., van Wyk, M., Baasov, T., Wolfrum, U., & Nagel‐Wolfrum, K.
- Venue
- EMBO Molecular Medicine
- Published
- 2012-10-02
- Volume
- 4
- Issue
- 11
- Pages
- 1186-1199
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W2157368702
- Cited by
- 102
- References
- 1
- FWCI
- 2.90
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.